AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU
AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe this week – but AbbVie's drug is the one to watch as analysts have dubbed it a potential blockbuster.
You may also be interested in...
AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.
AbbVie Hopes Imbruvica, Marivet Build Momentum Before Humira Downturn
With AbbVie's next-generation HCV combo Marivet, newly approved in Europe, the company can look to it and growing sales from Imbruvica to help make up for Humira revenue losses that may start in 2018.
Gilead Completes HCV Clinical Development With Vosevi Approval
Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.